Nabriva Therapeutics AG (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $12.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 20.00% from the company’s previous close.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
NBRV has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday, May 12th. Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics AG and gave the stock a “buy” rating in a research note on Monday, June 5th. Wedbush restated an “outperform” rating and set a $13.00 price target on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. Finally, ValuEngine upgraded Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $15.43.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 10.00 on Thursday. The stock’s 50 day moving average price is $10.40 and its 200-day moving average price is $10.35. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $12.75. The stock’s market cap is $268.38 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.34 million. Equities analysts anticipate that Nabriva Therapeutics AG will post ($2.43) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Nabriva Therapeutics AG (NASDAQ:NBRV) Lifted to Buy at Zacks Investment Research” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/08/12/nabriva-therapeutics-ag-nasdaqnbrv-lifted-to-buy-at-zacks-investment-research.html.
In other Nabriva Therapeutics AG news, Director George Harrison Talbot sold 325 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total value of $32,682.00. Following the transaction, the director now directly owns 3,854 shares in the company, valued at approximately $387,558.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Hbm Healthcare Investments (Ca sold 44,231 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $10.50, for a total value of $464,425.50. Following the completion of the transaction, the insider now owns 2,421,367 shares in the company, valued at $25,424,353.50. The disclosure for this sale can be found here. Insiders sold a total of 242,708 shares of company stock worth $2,646,784 over the last quarter.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors increased its position in shares of Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares during the period. Almanack Investment Partners LLC. increased its position in shares of Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after buying an additional 751,366 shares during the period. Wellington Management Group LLP increased its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Nabriva Therapeutics AG during the fourth quarter valued at $103,000. Institutional investors own 56.65% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.